Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of the latest interim data from a Phase
II, multi-center, randomized, dose-ranging clinical trial evaluating the
safety and antiviral activity of MK-5172, for the treatment of chronic
hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an
investigational, once-daily, oral HCV NS3/4A protease inhibitor that in
preclinical evaluations has demonstrated a high barrier to resistance.
Language:
English
Contact HTML:
MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Politics | Urology & Nephrology